Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain: a JORTC-PAL16 trial protocol.
Hiromichi MatsuokaKatherine ClarkBelinda FazekasShunsuke OyamadaLinda BrownHiroto IshikiYoshinobu MatsudaHideaki HasuoKeisuke AriyoshiJessica LeeBrian LePeter AllcroftSlavica KochovskaNoriko FujiwaraTempei MiyajiMelanie LovellMeera AgarTakuhiro YamaguchiEriko SatomiSatoru IwaseJane PhillipsAtsuko KoyamaDavid Christopher CurrowPublished in: BMJ open (2022)
Ethics approval was obtained at Osaka City University Hospital Certified Review Board and South Western Sydney Local Health District Human Research Ethics Committee. The results of this study will be submitted for publication in international journals and the key findings presented at international conferences. TRIAL REGISTRATION NUMBERS: jRCTs051190097, ACTRN12620000656932.
Keyphrases
- phase iii
- double blind
- clinical trial
- study protocol
- open label
- placebo controlled
- public health
- phase ii
- chronic pain
- randomized controlled trial
- neuropathic pain
- pain management
- south africa
- endothelial cells
- healthcare
- big data
- papillary thyroid
- mental health
- global health
- machine learning
- cross sectional
- squamous cell
- climate change
- young adults
- systematic review
- spinal cord injury
- spinal cord
- lymph node metastasis
- deep learning
- childhood cancer